A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
The aim of the trial is to assess the benefit of adding high precision radiation therapy to chemotherapy and surgery for the treatment of pancreatic cancer.
Primary Sponsor
Australasian Gastro-Intestinal Trials Group (AGITG)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG) and NHMRC CTC
Accrual Target
120
Expected Date of Accrual
31 December 2024
Trial Chairperson
Dr Andrew Oar, Gold Coast University Hospital
Trial Contact
MASTERPLAN.study@sydney.edu.au
Clinical Trial Registration
Related Post
26 March, 2026
TROG welcomes new Board members and President-Elect
LATEST NEWS: 26 March 2026 We are delighted to
26 March, 2026
TROG’S 38th ASM puts focus on driving innovative trials
LATEST NEWS: 26 March 2026 TROG’s 2026 Annual Scientific